Therapeutics News and Research

RSS

Staph-killing compound may be effective against osteomyelitis

Osteomyelitis - a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria - is particularly challenging to treat.

20 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Fibromyalgia, a painful condition affecting approximately 10 million people in the U.S., is not imaginary after all, as some doctors have believed. A discovery, published this month in PAIN MEDICINE (the journal of the American Academy of Pain Medicine), clearly now demonstrates that fibromyalgia may have a rational biological basis located in the skin.

19 Jun 2013

Researchers identify biochemical pathway essential for promoting head and neck cancer

A study led by researchers at The Ohio State University Comprehensive Cancer Center-- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified a biochemical pathway in cancer stem cells that is essential for promoting head and neck cancer.

19 Jun 2013

Research findings may pave way for new strategy to combat lung cancer

Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.

19 Jun 2013

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.

15 Jun 2013

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

15 Jun 2013

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet, a delayed-release formulation of generic metformin, at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL.

15 Jun 2013

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

15 Jun 2013

TAU researcher develops peptide to protect and restore microtubule function

A structure called "the microtubule network" is a crucial part of our nervous system. It acts as a transportation system within nerve cells, carrying essential proteins and enabling cell-to-cell communications. But in neurodegenerative diseases like Alzheimer's, ALS, and Parkinson's, this network breaks down, hindering motor abilities and cognitive function.

14 Jun 2013

Osseon releases Osseoflex CD-H hydraulic cement delivery system

Osseon announces the release of the Osseoflex CD-H hydraulic cement delivery system. This latest addition to the Osseon product line is designed for delivery of medium to high viscosity bone cement during the treatment of vertebral compression fractures.

14 Jun 2013

Research findings could enable early screening of HCC patients for more aggressive treatment

Latest research findings by scientists at the Cancer Science Institute of Singapore at the National University of Singapore could enable early screening of patients with hepatocellular carcinoma, a major form of liver cancer, for more aggressive treatment to improve survival rate.

14 Jun 2013

Mount Sinai researchers produce cells that resemble hematopoietic stem cells

By transferring four genes into mouse fibroblast cells, researchers at the Icahn School of Medicine at Mount Sinai have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day.

14 Jun 2013

Research could enable early screening of liver cancer patients to improve survival rate

Latest research findings by scientists at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) could enable early screening of patients with hepatocellular carcinoma (HCC), a major form of liver cancer, for more aggressive treatment to improve survival rate.

13 Jun 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Therapeutics News and Research

Staph-killing compound may be effective against osteomyelitis

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Researchers discover a rational source of pain in skin of patients with fibromyalgia

Researchers identify biochemical pathway essential for promoting head and neck cancer

Research findings may pave way for new strategy to combat lung cancer

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

Transition, Lilly amend agreement to address future development of TT-401

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Elcelyx Therapeutics' posters related to NewMet to be presented at ADA's 73rd Scientific Sessions

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

TAU researcher develops peptide to protect and restore microtubule function

Osseon releases Osseoflex CD-H hydraulic cement delivery system

Research findings could enable early screening of HCC patients for more aggressive treatment

Mount Sinai researchers produce cells that resemble hematopoietic stem cells

Research could enable early screening of liver cancer patients to improve survival rate

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Latest News